#Array BioPharma (ARRY) - Prohost Biotech

Pfizer to Acquire Array Biopharma at $48 a Share

Pfizer to Acquire Array Pfizer (PFE) announced that it has agreed to acquire Array Biopharma (ARRY) in a deal valued at $11.4 billion. The Terms of the Agreement Under the terms of the agreement, Pfi...

P

Prohost Biotech

Jun 17, 2019

The ASCO 2019 Special Edition

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed victim of the instigated and irrelevant fear against investing in the stock market is the market itse...

P

Prohost Biotech

Jun 11, 2019

Array BioPharma: Great News and a Learning Experience

Great News for Array BioPharma Array BioPharma ( ARRY ) announced positive results from the interim analysis of the Phase 3 BEACON CRC trial. The trial evaluates the combination of: Braftovi ® (enco...

P

Prohost Biotech

May 21, 2019

During the Departed Week

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week Highs The three picks referred to in the above title are, Novartis (NVS), Array (AARY) and Ionis (IONS)...

P

Prohost Biotech

Mar 19, 2019

The molecule that enhanced the T Cells cancer treatment efficacy while preventing autoimmune diseases

Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we keep reminding ourselves are undervalued. The outperformance unveiled the interred strength of firms s...

P

Prohost Biotech

Nov 8, 2018

1m

6

News & Comments

Observing Array Biopharma

A number of biotech or biopharmaceutical companies have succeeded in the past couple of years in changing their statuses from clinical stage to revenues-generating firms. A number of these firms resid...

P

Prohost Biotech

Oct 31, 2018

Three important news

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across a lot of news announcing research, clinical trial results, collaborations, product approvals and acquisitions. Much of th...

P

Prohost Biotech

Sep 25, 2018

Vertex has good news from Australia. Why selling solid firms stocks.

Vertex Pharmaceuticals (VRTX) announced that the Pharmaceutical Benefits Advisory Committee’s (PBAC) in Australia recommendation the listing of Orkambi ® (lumacaftor/ivacaftor) on the Pharmaceutical...

P

Prohost Biotech

Aug 21, 2018

Finding reasons for underperforming stocks

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know why some of their stocks plummet when no bad news is broadcast anywhere and when firms announce ter...

P

Prohost Biotech

Jul 2, 2018

1m

0

News & Comments

The FDA approved a combination of two products. Both belong to Array Biopharma

The FDA approved Array BioPharma’s (ARRY) products Braftovi™ capsules in combination with Mektovi® tablets for unresectable or metastatic skin cancer melanoma with a BRAF or BRAFV mutation, as detecte...

P

Prohost Biotech

Jun 28, 2018

Good News, Bad News & Comebacks. See Also: ASCO Results

The Week in Review #23 ASCO 2018 - Small publicly-traded oncology biotech firms, large oncology biotech firms, and giant biopharmaceutical firms, in addition to some private biot...

P

Prohost Biotech

Jun 19, 2018

More promising news for Array from its melanoma combination clinical trial

Array BioPharma (ARRY) announced updated results from the Phase 3 COLUMBUS trial in BRAF -mutant advanced melanoma. The results showed that the median overall survival (mOS ) was 33.6 months for pa...

P

Prohost Biotech

Jun 5, 2018

Bull or Bear

The Week in Review #20 THE MARKET - My friend asked: “Are you scared?” “Of what?” I asked “The market?” The market? No,” I said. We are afraid of those who are rendering the market nervous and...

P

Prohost Biotech

Mar 26, 2018

Exelixis’ and Array’s Enchanting News

Exelixis: Delightful Overseas Cabozantinib News Ipsen (EPA:IPN) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EM...

P

Prohost Biotech

Mar 23, 2018

Observing Queer Stories

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an important factor Xa inhibitor Bevyxxa (betrixa-ban for extended prophylaxis of venous thromboemb...

P

Prohost Biotech

Mar 2, 2018

1m

4

News & Comments

Celgene Acquires Juno Therapeutics at $9 Billion or $87 a Share. Why Array is Trading Around $15 in Premarket Today.

Celgene (CELG) and Juno (JUNO) announced the signing of a definitive merger agreement upon which Celgene has agreed to acquire Juno. Celgene will pay $87 per share in cash, or a total of approximately...

P

Prohost Biotech

Jan 22, 2018

Some Small Outperforming Biotech Firms

The Week in Review #4 AMAZING STOCK REBOUNDING - We have already witnessed and wrote about the fierce rebounding of some of our selected stocks comprising: Exelixis (EXEL), Sangamo (SGMO), Array (ARRY...

P

Prohost Biotech

Sep 18, 2017

The STAR of the Week

THE WEEK IN REVIEW Wall Street As we said in yesterday’s article posted under Today’s Highlights, stocks can plummet at any time, regardless of whether they have the best or the worst grades for their...

P

Prohost Biotech

Aug 20, 2017

Targeted Drugs That Would Improve on Immunotherapy Treatments' Outcomes. See Array and Exelixis

FROM ARRAY Array’s Drug Binimetinib in Combination Therapy with Merck’s Drug Keytruda for METASTATIC FOR COLORECTAL CANCER On May 8, 2017, Array BioPharma and Merck announced entering into a clinica...

P

Prohost Biotech

Jul 10, 2017

Celgene and Immunotherapy: An Unfolding Story

As we wrote yesterday, immunotherapy checkpoint inhibitors represent a great advancement and big changes in the management of cancer. It is pertinent, though, to keep in mind that these immuno-oncolog...

P

Prohost Biotech

Jul 8, 2017

1m

4